Receptor structure-based virtual screening identifies a promising p38α inhibitor

The FDA ap­proval of Am­gen’s in­ter­change­able Ste­lara biosim­i­lar is rais­ing broad­er ques­tions about how po­ten­tial com­pe­ti­tion could im­pact Medicare price ne­go­ti­a­tions for John­son & John­son’s

Su­ki, a start­up that pro­vides AI tools to help health­care providers with doc­u­men­ta­tion, billing and oth­er ad­min­is­tra­tive work, raised $70 mil­lion in a Se­ries D